- Home
- AUPH vs ANIP Comparison
AUPH vs ANIP Comparison
Compare AUPH & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- ANIP
- Stock Information
- Founded
- AUPH 1993
- ANIP 2001
- Country
- AUPH Canada
- ANIP United States
- Employees
- AUPH N/A
- ANIP N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- ANIP Health Care
- Exchange
- AUPH Nasdaq
- ANIP Nasdaq
- Market Cap
- AUPH 1.1B
- ANIP 1.2B
- IPO Year
- AUPH 1999
- ANIP N/A
- Fundamental
- Price
- AUPH $8.05
- ANIP $68.02
- Analyst Decision
- AUPH Strong Buy
- ANIP Strong Buy
- Analyst Count
- AUPH 2
- ANIP 8
- Target Price
- AUPH $11.50
- ANIP $79.75
- AVG Volume (30 Days)
- AUPH 1.4M
- ANIP 361.8K
- Earning Date
- AUPH 05-01-2025
- ANIP 05-09-2025
- Dividend Yield
- AUPH N/A
- ANIP N/A
- EPS Growth
- AUPH N/A
- ANIP N/A
- EPS
- AUPH 0.04
- ANIP N/A
- Revenue
- AUPH $235,133,000.00
- ANIP $614,376,000.00
- Revenue This Year
- AUPH $11.86
- ANIP $27.62
- Revenue Next Year
- AUPH $24.96
- ANIP $7.71
- P/E Ratio
- AUPH $201.00
- ANIP N/A
- Revenue Growth
- AUPH 33.97
- ANIP 26.20
- 52 Week Low
- AUPH $4.71
- ANIP $52.50
- 52 Week High
- AUPH $10.67
- ANIP $70.00
- Technical
- Relative Strength Index (RSI)
- AUPH 44.83
- ANIP 66.14
- Support Level
- AUPH $7.93
- ANIP $65.28
- Resistance Level
- AUPH $8.73
- ANIP $69.33
- Average True Range (ATR)
- AUPH 0.23
- ANIP 2.32
- MACD
- AUPH -0.04
- ANIP 0.29
- Stochastic Oscillator
- AUPH 15.00
- ANIP 83.54
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.